| 0.9725 -0.002 (-0.16%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.19 | 1-year : | 1.28 |
| Resists | First : | 1.02 | Second : | 1.1 |
| Pivot price | 1.01  |
|||
| Supports | First : | 0.89 | Second : | 0.74 |
| MAs | MA(5) : | 0.97 |
MA(20) : | 1.01 |
| MA(100) : | 1.22 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.1 |
D(3) : | 15.9 |
| RSI | RSI(14): 42.3 |
|||
| 52-week | High : | 2.67 | Low : | 0.89 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ COCP ] has closed above bottom band by 23.8%. Bollinger Bands are 42.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.99 - 1 | 1 - 1 |
| Low: | 0.93 - 0.94 | 0.94 - 0.94 |
| Close: | 0.96 - 0.97 | 0.97 - 0.98 |
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Thu, 18 Dec 2025
Human trial of first oral drug to fight norovirus cleared at Emory - Stock Titan
Mon, 01 Dec 2025
Cocrystal Pharma, Inc. to Present Clinical Progress Update at NobleCon 21 Conference - Quiver Quantitative
Fri, 28 Nov 2025
Phillip Frost buys Cocrystal Pharma (COCP) shares worth $3975 - Investing.com
Fri, 14 Nov 2025
Cocrystal Pharma Reports Third Quarter 2025 Financial - GlobeNewswire
Mon, 27 Oct 2025
Cocrystal (Nasdaq: COCP) receives NIH SBIR Phase I award, ~$500K for influenza antiviral - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 32.4 (%) |
| Held by Institutions | 4.8 (%) |
| Shares Short | 139 (K) |
| Shares Short P.Month | 262 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.8 % |
| Return on Equity (ttm) | -95 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -1.05 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.4 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|